Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31324714 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2ACA14 | |
| SCHEMBL30240854 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2ACA14 | |
| SCHEMBL933475 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2ACA14 | |
| SCHEMBL31649022 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2ACA14 | |
| SCHEMBL31324738 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2ACA14 | |
| SCHEMBL31324778 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2ACA14 | |
| SCHEMBL31324781 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2ACA14 | |
| SCHEMBL29865581 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2ACA14 | |
| SCHEMBL20514675 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2ACA14 | |
| SCHEMBL10632304 | 0.98 | SMN1; SMN2 (0.33) | SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119818698-A | Micro-molecular drug conjugate based on anisoamide targeted human prostate cancer cells, preparation method and application thereof | 华东师范大学 | 2025-04-15 | — | — | CN | claimed |
| CN-119015137-A | Nanometer microemulsion and preparation method and application thereof | 广州真极和美生物科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| EP-4157853-B1 | GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS | GIIANT PHARMA INC (CA) | 2024-07-31 | — | — | EP | claimed |
| CN-113956321-B | Estradiol 6-glucuronide and preparation method and application thereof | 郑州安图生物工程股份有限公司 | 2023-11-03 | — | — | CN | claimed |
| CN-115505020-B | Ursolic acid saponin and its preparation method and use | 沈阳药科大学 | 2023-09-12 | — | — | CN | claimed |
| US-20230250123-A1 | GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS | GIIANT PHARMA INC. (CA) | 2023-08-10 | — | — | US | claimed |
| CN-116056713-A | Intestinal microbiota bioactive PDE4 inhibitor precursors | 吉安特制药公司 | 2023-05-02 | — | — | CN | claimed |
| EP-4157853-A1 | GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS | Giiant Pharma Inc. (CA) | 2023-04-05 | — | — | EP | claimed |
| CN-115368300-B | Compound for TLR8 inhibitor and preparation method and application thereof | 北京拓领博泰生物科技有限公司 | 2023-03-24 | — | — | CN | claimed |
| WO-2023040733-A1 | BAICALEIN DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-03-23 | — | — | WO | claimed |
| CN-106727508-A | A kind of combination drug for treating chronic dysentery | 郑州掌盟网络科技有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-104693163-B | Method for preparing corresponding aglycon with glucuronide as raw material | 中国药科大学 | 2017-01-18 | — | — | CN | claimed |
| CN-106146573-A | Leonurine metabolite and preparation method thereof | 复旦大学 | 2016-11-23 | — | — | CN | claimed |
| CN-104693163-A | Method for preparing corresponding aglycon with glucuronide as raw material | UNIV CHINA PHARMA | 2015-06-10 | — | — | CN | claimed |
| CN-102846644-A | Application of natural pentacyclic triterpenoid in preparation of medicines capable of inhibiting activity of blood coagulation factor Xa | JIANGSU PROVINCIAL ACADEMY TRADITIONAL CHINESE MEDICINE | 2013-01-02 | — | — | CN | claimed |
| CN-101385776-A | Anti influenza use of main chemical component and active component in scabriculous herbamoslae | INST MATERIA MEDICA CAMS (CN) | 2009-03-18 | — | — | CN | claimed |
| EP-0511917-B1 | Glycosylated prodrugs, process for their preparation and uses thereof | HOECHST SA LAB (FR) | 1996-10-23 | — | — | EP | claimed |
| US-5561119-A | ANTITUMOR AGENTS | LABORATOIRES HOECHST (FR) | 1996-10-01 | — | — | US | claimed |
| US-4683222-A | STIMULANTS FOR IMMUNE SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1987-07-28 | — | — | US | claimed |
| US-4351937-A | N-Glycosyl derivatives of anthracycline antibiotics and the method of their preparation | POLITECHNIKA GDANSKA (PL) | 1982-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250123-A1 | GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS | PDE4A, PDE4B, PDE4C | SMN1; SMN2 1713/4885KMT2A 3668/4885CA14 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.